Abstract：
OBJECTIVE: To estimate long-term prognosis of chemosensory dysfunctions among patients recovering from COVID-19 disease.
METHODS: Between April 2020 and July 2022, we conducted a prospective, observational study enrolling 48 patients who experienced smell and/or taste dysfunction during the acute-phase of COVID-19. Patients were evaluated for chemosensory function up to 24 months after disease onset.
RESULTS: During the acute-phase of COVID-19, 80% of patients reported anosmia, 15% hyposmia, 63% ageusia, and 33% hypogeusia. At two years\' follow-up, 53% still experienced smell impairment, and 42% suffered from taste impairment. Moreover, 63% of patients who reported parosmia remained with olfactory disturbance. Interestingly, we found a negative correlation between visual analogue scale scores for smell and taste impairments during the acute-phase of COVID-19 and the likelihood of long-term recovery.
CONCLUSIONS: Our study sheds light on the natural history and long-term follow-up of chemosensory dysfunction in patients recovering from COVID-19 disease. Most patients who initially suffered from smell and/or taste disturbance did not reach full recovery after 2 years follow-up. The severity of impairment may serve as a prognostic indicator for full recovery.
METHODS: Between April 2020 and July 2022, we conducted a prospective, observational study enrolling 48 patients who experienced smell and/or taste dysfunction during the acute-phase of COVID-19. Patients were evaluated for chemosensory function up to 24 months after disease onset.
RESULTS: During the acute-phase of COVID-19, 80% of patients reported anosmia, 15% hyposmia, 63% ageusia, and 33% hypogeusia. At two years\' follow-up, 53% still experienced smell impairment, and 42% suffered from taste impairment. Moreover, 63% of patients who reported parosmia remained with olfactory disturbance. Interestingly, we found a negative correlation between visual analogue scale scores for smell and taste impairments during the acute-phase of COVID-19 and the likelihood of long-term recovery.
CONCLUSIONS: Our study sheds light on the natural history and long-term follow-up of chemosensory dysfunction in patients recovering from COVID-19 disease. Most patients who initially suffered from smell and/or taste disturbance did not reach full recovery after 2 years follow-up. The severity of impairment may serve as a prognostic indicator for full recovery.
摘要：
目的：评估COVID-19疾病恢复期患者化学感受功能障碍的长期预后。
方法：在2020年4月至2022年7月之间，我们进行了前瞻性，观察性研究纳入48名在COVID-19急性期出现嗅觉和/或味觉功能障碍的患者。在疾病发作后24个月内对患者的化学感受功能进行评估。
结果：在COVID-19急性期，80%的患者报告无嗅觉，15%食子不足,63%的退赛，和33%的伪善。在两年的随访中，53%的人仍有嗅觉障碍，42%的人患有味觉障碍。此外，63％的报告的患者仍有嗅觉障碍。有趣的是,我们发现,COVID-19急性期嗅觉和味觉障碍的视觉模拟评分与长期康复的可能性呈负相关.
结论：我们的研究揭示了COVID-19疾病康复患者化学感受功能障碍的自然史和长期随访。大多数最初患有嗅觉和/或味觉障碍的患者在2年随访后没有完全康复。损伤的严重程度可以作为完全恢复的预后指标。
方法：在2020年4月至2022年7月之间，我们进行了前瞻性，观察性研究纳入48名在COVID-19急性期出现嗅觉和/或味觉功能障碍的患者。在疾病发作后24个月内对患者的化学感受功能进行评估。
结果：在COVID-19急性期，80%的患者报告无嗅觉，15%食子不足,63%的退赛，和33%的伪善。在两年的随访中，53%的人仍有嗅觉障碍，42%的人患有味觉障碍。此外，63％的报告的患者仍有嗅觉障碍。有趣的是,我们发现,COVID-19急性期嗅觉和味觉障碍的视觉模拟评分与长期康复的可能性呈负相关.
结论：我们的研究揭示了COVID-19疾病康复患者化学感受功能障碍的自然史和长期随访。大多数最初患有嗅觉和/或味觉障碍的患者在2年随访后没有完全康复。损伤的严重程度可以作为完全恢复的预后指标。
